170570-75-9 : Celecoxib Bromo Impurity
It is a selective cyclooxygenase-2 inhibitor, By inhibiting prostaglandin synthesis non-steroidal anti-inflammatory drugs cause mucosal damage and ulceration. Celecoxib poses less of an ulceration risk than other NSAIDS, owing to its decreased effect on gastric mucosal prostaglandin synthesis when compared to placebo, also exerts anticancer effects by binding to the cadherin-11 protein, which is involved in the progression of tumors and inhibiting the 3 phosphoinositide-dependent kinase-1 signaling mechanism, which is used to treat osteoarthritis, rheumatoid arthritis, and to reduce polyps in familial adenomatous polyposis.
Additional information on CAS 170570-75-9
Xu, C., Gu, K., Yasen, Y., & Hou, Y. (2016). Efficacy and Safety of Celecoxib Therapy in Osteoarthritis. Medicine, 95(20), e3585. https://doi.org/10.1097/md.0000000000003585
Other products related to celecoxib
|Name of Impurity||Catalogue No.|